SEHK:1177Pharmaceuticals
Why Sino Biopharmaceutical (SEHK:1177) Is Up 8.2% After New Global Respiratory Deals And NDA Milestone
In recent days, Sino Biopharmaceutical announced that its subsidiary Beijing Tide had an NDA for a world-first long-acting ropivacaine hydrochloride sustained-release solution for postoperative analgesia accepted by China’s Center for Drug Evaluation, while another subsidiary granted AstraZeneca exclusive ex-China rights to the inhaled respiratory drug TQC3721 and expanded a respiratory medicines partnership with GSK in mainland China.
The AstraZeneca licence, which includes a US$200 million...